Cargando…

Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action

We tried to review and update clinical and preclinical studies evaluating vilazodone's role as an antidepressant for patients with major depressive disorder (MDD). In terms of its mechanism of actions, we sought to elaborate them mainly through preclinical animal studies. A data search was cond...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sheng-Min, Han, Changsu, Lee, Soo-Jung, Patkar, Ashwin A, Masand, Prakash S, Pae, Chi-Un
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neuropsychiatric Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390584/
https://www.ncbi.nlm.nih.gov/pubmed/25866514
http://dx.doi.org/10.4306/pi.2015.12.2.155
_version_ 1782365702592659456
author Wang, Sheng-Min
Han, Changsu
Lee, Soo-Jung
Patkar, Ashwin A
Masand, Prakash S
Pae, Chi-Un
author_facet Wang, Sheng-Min
Han, Changsu
Lee, Soo-Jung
Patkar, Ashwin A
Masand, Prakash S
Pae, Chi-Un
author_sort Wang, Sheng-Min
collection PubMed
description We tried to review and update clinical and preclinical studies evaluating vilazodone's role as an antidepressant for patients with major depressive disorder (MDD). In terms of its mechanism of actions, we sought to elaborate them mainly through preclinical animal studies. A data search was conducted in November 1, 2013, using the key terms "vilazodone" or "Viibryd," in PubMed and Medline databases. All published and unpublished studies are included and citations from publications were also reviewed for additional references. Five unpublished, phase-II and two pivotal published phase-III clinical trials with nearly identical design (8-week, double-blind, randomized, and placebo-controlled) investigated efficacy of vilazodone, were found for the treatment of patients with MDD. Two post-hoc studies and one long-term open study were also included. Data were thoroughly reviewed to incorporate the pharmacology, action mechanism, efficacy and safety for the vilazodone in the treatment of major depressive disorder. Vilazodone is an antidepressant with novel mechanism of action because its chemical structure is unrelated to conventional antidepressant, and it has a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile. Vilazodone is an effective and safe treatment option with its novel action mechanisms for patients with depression. Its putative benefits compared with other antidepressants must be thoroughly studied in adequately-powered and well-designed future clinical trials.
format Online
Article
Text
id pubmed-4390584
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Korean Neuropsychiatric Association
record_format MEDLINE/PubMed
spelling pubmed-43905842015-04-10 Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action Wang, Sheng-Min Han, Changsu Lee, Soo-Jung Patkar, Ashwin A Masand, Prakash S Pae, Chi-Un Psychiatry Investig Review Article We tried to review and update clinical and preclinical studies evaluating vilazodone's role as an antidepressant for patients with major depressive disorder (MDD). In terms of its mechanism of actions, we sought to elaborate them mainly through preclinical animal studies. A data search was conducted in November 1, 2013, using the key terms "vilazodone" or "Viibryd," in PubMed and Medline databases. All published and unpublished studies are included and citations from publications were also reviewed for additional references. Five unpublished, phase-II and two pivotal published phase-III clinical trials with nearly identical design (8-week, double-blind, randomized, and placebo-controlled) investigated efficacy of vilazodone, were found for the treatment of patients with MDD. Two post-hoc studies and one long-term open study were also included. Data were thoroughly reviewed to incorporate the pharmacology, action mechanism, efficacy and safety for the vilazodone in the treatment of major depressive disorder. Vilazodone is an antidepressant with novel mechanism of action because its chemical structure is unrelated to conventional antidepressant, and it has a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile. Vilazodone is an effective and safe treatment option with its novel action mechanisms for patients with depression. Its putative benefits compared with other antidepressants must be thoroughly studied in adequately-powered and well-designed future clinical trials. Korean Neuropsychiatric Association 2015-04 2015-03-18 /pmc/articles/PMC4390584/ /pubmed/25866514 http://dx.doi.org/10.4306/pi.2015.12.2.155 Text en Copyright © 2015 Korean Neuropsychiatric Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Wang, Sheng-Min
Han, Changsu
Lee, Soo-Jung
Patkar, Ashwin A
Masand, Prakash S
Pae, Chi-Un
Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
title Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
title_full Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
title_fullStr Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
title_full_unstemmed Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
title_short Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
title_sort vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390584/
https://www.ncbi.nlm.nih.gov/pubmed/25866514
http://dx.doi.org/10.4306/pi.2015.12.2.155
work_keys_str_mv AT wangshengmin vilazodoneforthetreatmentofmajordepressivedisorderfocusingonitsclinicalstudiesandmechanismofaction
AT hanchangsu vilazodoneforthetreatmentofmajordepressivedisorderfocusingonitsclinicalstudiesandmechanismofaction
AT leesoojung vilazodoneforthetreatmentofmajordepressivedisorderfocusingonitsclinicalstudiesandmechanismofaction
AT patkarashwina vilazodoneforthetreatmentofmajordepressivedisorderfocusingonitsclinicalstudiesandmechanismofaction
AT masandprakashs vilazodoneforthetreatmentofmajordepressivedisorderfocusingonitsclinicalstudiesandmechanismofaction
AT paechiun vilazodoneforthetreatmentofmajordepressivedisorderfocusingonitsclinicalstudiesandmechanismofaction